Ezogabine
- Generic Name
- Ezogabine
- Drug Type
- Small Molecule
- Chemical Formula
- C16H18FN3O2
- CAS Number
- 150812-12-7
- Unique Ingredient Identifier
- 12G01I6BBU
- Background
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
- Indication
Adjuvant treatment of partial-onset seizures.
- Associated Conditions
- Refractory Partial Onset Seizures
Risk of Urinary Retention With Retigabine
- Conditions
- Epilepsy
- Interventions
- Drug: Non-EZG containing AED polytherapyDrug: Non-EZG AED monotherapy
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01462656
Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 98
- Registration Number
- NCT01336621
- Locations
- 🇺🇦
GSK Investigational Site, Poltava, Ukraine
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 203
- Registration Number
- NCT01227902
- Locations
- 🇺🇦
GSK Investigational Site, Poltava, Ukraine
Bioavailability of Different n-3 Fatty Acid Formulations
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- Gottfried Wilhelm Leibniz Universität Hannover
- Target Recruit Count
- 12
- Registration Number
- NCT01214278
- Locations
- 🇩🇪
Gottfried Wilhelm leibniz University of Hanover, Hanover, Lower Saxony, Germany
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT00612105
Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 376
- Registration Number
- NCT00310388
- Locations
- 🇦🇺
Institute of Clniical Neurosciences, Camperdown, New South Wales, Australia
🇦🇺North Coast Neurology Centre, Maroochydore, Queensland, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 539
- Registration Number
- NCT00235755
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸Neurological Clinic-Texas, Dallas, Texas, United States
🇩🇪University of Bonn -- Department for Epileptplogy, Bonn, Germany
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 306
- Registration Number
- NCT00232596
- Locations
- 🇺🇸
McFarland Clinic, Ames, Iowa, United States
🇺🇸Oregon Neurology PC, Tualatin, Oregon, United States
🇦🇷Fundacion Lennox, Cordoba, CRD, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.